CELU on Nasdaq
Celularity Inc
American pharmaceutical preparations company based in Florham Park.
$1.31 up 0.00 (0.00%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 18, 2026.
Overview
Compare with Cue Biopharma, Inc., Entrada Therapeutics, Inc. or ALUMIS INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 50% of the revenue Celularity Inc broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $35.3M | $13.2M |
| License Royalty and Other | $13.7M | $7.9M |
| Service | $5.1M | $5.4M |
Business segments
Degenerative Disease brought in 65% of the revenue Celularity Inc broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Degenerative Disease | $48.4M | $17.3M |
| Biobanking | $5.1M | $5.4M |
| Cell Therapy | $688.0K | $3.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue23¢$20.1M
- Research and development17¢$15.0M
- Selling, general and admin59¢$51.3M
- Income tax0¢$3.0K
Out of $26.6M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues | $26.6M | $54.2M |
| Cost of revenues | $20.1M | $15.0M |
| Research and development | $15.0M | $17.4M |
| Selling, general and administrative | $51.3M | $58.6M |
| Change in fair value of contingent consideration liability | -$193.0K | |
| Amortization of acquired intangible assets | $1.5M | $1.8M |
| Total operating expenses | $87.9M | $92.6M |
| Loss from operations | -$61.3M | -$38.4M |
| Interest income | $262.0K | $331.0K |
| Interest expense | -$6.8M | -$6.3M |
| Change in fair value of warrant liabilities | -$3.3M | $398.0K |
| Change in fair value of derivative liability | $65.0K | |
| Change in fair value of debt | -$1.8M | -$492.0K |
| Loss on debt extinguishment | -$6.4M | -$3.9M |
| Amortization of licensing obligation premium | $1.9M | |
| Loss on issuance of convertible notes with warrants | -$2.3M | |
| Impairment of preferred stock investment | -$2.9M | |
| Compliance fees and other expense, net | -$9.2M | -$9.6M |
| Total other expense | -$30.4M | -$19.5M |
| Loss before income taxes | -$91.7M | -$57.9M |
| Income tax expense (benefit) | $3.0K | |
| Net loss | -$91.7M | -$57.9M |
| Deemed dividend relating to inducement of Dragasac warrants | -$64.0K | |
| Paid-in kind preferred stock dividend | -$20.0K | |
| Net loss attributable to common shareholders | -$91.8M | -$57.9M |
| Net loss per share - basic | -$3.59 | -$2.64 |
| Net loss per share - diluted | -$3.59 | -$2.64 |
| Weighted average shares outstanding - basic | 25.6M shares | 21.9M shares |
| Weighted average shares outstanding - diluted | 25.6M shares | 21.9M shares |
| Change in fair value of debt due to change in credit risk | $5.0K | -$5.0K |
| Comprehensive loss | -$91.7M | -$57.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $6.2M | $738.0K | |
| Accounts receivable, net of allowance of $7,647 and $6,294 as of December 31, 2025 and 2024, respectively | $4.7M | $13.6M | |
| Inventory | $571.0K | $5.4M | |
| Prepaid expenses and other current assets | $920.0K | $857.0K | |
| Total current assets | $12.3M | $20.6M | |
| Property and equipment, net | $55.8M | $61.6M | |
| Goodwill | $7.3M | $7.3M | $7.3M |
| Intangible assets, net | $7.8M | $9.2M | |
| Right-of-use assets - operating | $10.7M | $10.8M | |
| Restricted cash | $10.2M | $10.2M | |
| Inventory, net of current portion | $2.9M | $12.6M | |
| Other long-term assets | $247.0K | $270.0K | |
| Total assets | $107.3M | $132.7M | |
| Accounts payable | $26.4M | $23.3M | |
| Accrued expenses and other current liabilities | $32.6M | $20.5M | |
| Short-term license obligation | $2.1M | ||
| Deferred revenue | $5.3M | $3.5M | |
| Preferred stock redemption liability | $300.0K | ||
| Derivative liability | $92.0K | ||
| Total current liabilities | $80.8M | $53.7M | |
| Deferred revenue, net of current portion | $2.8M | $2.7M | |
| Noncurrent acquisition - related contingent consideration | $1.4M | $1.4M | |
| Noncurrent lease liabilities - operating | $26.9M | $26.5M | |
| Warrant liabilities | $1.5M | $3.3M | |
| Long-term license obligation | $31.7M | ||
| Deferred income tax liabilities | $12.0K | $9.0K | |
| Other liabilities | $266.0K | $280.0K | |
| Total liabilities | $145.4M | $123.8M | |
| Common Stock, $0.0001 par value, 730,000,000 shares authorized; 28,837,787 and 22,546,671 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $2.0K | |
| Additional paid-in capital | $953.4M | $908.5M | |
| Accumulated other comprehensive loss | -$5.0K | ||
| Accumulated deficit | -$991.5M | -$899.7M | |
| Total stockholders(deficit) equity | -$38.1M | $8.8M | $41.0M |
| Total liabilities and stockholders(deficit) equity | $107.3M | $132.7M | |
| Accounts receivable, allowance | $7.6M | $6.3M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 1.7M shares | 0 shares | |
| Preferred stock, shares outstanding | 1.7M shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 730.0M shares | 730.0M shares | |
| Common stock, shares issued | 28.8M shares | 22.5M shares | |
| Common stock, shares outstanding | 28.8M shares | 22.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $6.2M | $738.0K | |
| Accounts receivable, net of allowance of $7,647 and $6,294 as of December 31, 2025 and 2024, respectively | $4.7M | $13.6M | |
| Inventory | $571.0K | $5.4M | |
| Prepaid expenses and other current assets | $920.0K | $857.0K | |
| Total current assets | $12.3M | $20.6M | |
| Property and equipment, net | $55.8M | $61.6M | |
| Goodwill | $7.3M | $7.3M | $7.3M |
| Intangible assets, net | $7.8M | $9.2M | |
| Right-of-use assets - operating | $10.7M | $10.8M | |
| Restricted cash | $10.2M | $10.2M | |
| Inventory, net of current portion | $2.9M | $12.6M | |
| Other long-term assets | $247.0K | $270.0K | |
| Total assets | $107.3M | $132.7M | |
| Accounts payable | $26.4M | $23.3M | |
| Accrued expenses and other current liabilities | $32.6M | $20.5M | |
| Short-term license obligation | $2.1M | ||
| Deferred revenue | $5.3M | $3.5M | |
| Preferred stock redemption liability | $300.0K | ||
| Derivative liability | $92.0K | ||
| Total current liabilities | $80.8M | $53.7M | |
| Deferred revenue, net of current portion | $2.8M | $2.7M | |
| Noncurrent acquisition - related contingent consideration | $1.4M | $1.4M | |
| Noncurrent lease liabilities - operating | $26.9M | $26.5M | |
| Warrant liabilities | $1.5M | $3.3M | |
| Long-term license obligation | $31.7M | ||
| Deferred income tax liabilities | $12.0K | $9.0K | |
| Other liabilities | $266.0K | $280.0K | |
| Total liabilities | $145.4M | $123.8M | |
| Common Stock, $0.0001 par value, 730,000,000 shares authorized; 28,837,787 and 22,546,671 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $2.0K | |
| Additional paid-in capital | $953.4M | $908.5M | |
| Accumulated other comprehensive loss | -$5.0K | ||
| Accumulated deficit | -$991.5M | -$899.7M | |
| Total stockholders(deficit) equity | -$38.1M | $8.8M | $41.0M |
| Total liabilities and stockholders(deficit) equity | $107.3M | $132.7M | |
| Accounts receivable, allowance | $7.6M | $6.3M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 1.7M shares | 0 shares | |
| Preferred stock, shares outstanding | 1.7M shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 730.0M shares | 730.0M shares | |
| Common stock, shares issued | 28.8M shares | 22.5M shares | |
| Common stock, shares outstanding | 28.8M shares | 22.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$91.7M | -$57.9M |
| Depreciation and amortization | $7.3M | $7.9M |
| Non cash lease expense | $110.0K | $160.0K |
| Gain on amortization of licensing obligation | -$1.9M | |
| Provision for credit losses | $1.4M | $457.0K |
| Change in fair value of warrant liabilities | $3.3M | -$398.0K |
| Change in fair value of derivative liability | -$65.0K | |
| Inventory reserve for obsolescence | -$102.0K | -$186.0K |
| Inventory impairment | $4.3M | $466.0K |
| Impairment of preferred stock investment | $2.9M | |
| Loss on issuance of common stock to Yorkville in connection with the Side Letter | $382.0K | |
| Loss on issuance of common stock in connection with the settlement of debt | $73.0K | |
| Issuance of warrants for Strategic Advisory Agreement | $1.3M | |
| Issuance of common stock due to Strategic Advisory Agreement | $108.0K | |
| Loss on issuance of convertible note with warrants | $2.3M | |
| Issuance of warrants to preferred stockholders in consideration of forbearance agreement | $49.0K | |
| Gain on forgiveness of interest | -$991.0K | |
| Share-based compensation expense | $10.4M | $11.6M |
| Director fees paid with RSUs | $264.0K | |
| Issuance of common stock to Palantir as consideration for settlement agreement | $175.0K | |
| Issuance of common stock to Yorkville for debt extension and SEPA commitment fee | $317.0K | |
| Issuance of common stock for consulting expense | $705.0K | $158.0K |
| Change in fair value of contingent stock consideration | -$193.0K | |
| Loss on extinguishment of debt | $6.4M | $3.9M |
| Change in fair value of debt | $1.8M | $492.0K |
| Non cash interest expense | $4.9M | $4.1M |
| Other, net | $300.0K | |
| Accounts receivable | $7.6M | -$4.0M |
| Inventory | $10.2M | $6.3M |
| Prepaid expenses and other assets | -$40.0K | $905.0K |
| Accounts payable | $3.1M | $9.2M |
| Accrued expenses and other liabilities | $13.5M | $12.6M |
| Accrued R&D software | -$3.5M | |
| Lease liabilities | $350.0K | $371.0K |
| Deferred income tax liabilities | $3.0K | |
| Deferred revenue | -$1.1M | $235.0K |
| Net cash used in operating activities | -$13.3M | -$6.4M |
| Capital expenditures | -$161.0K | |
| Rebound asset acquisition | -$1.5M | |
| Proceeds from Sanuwave convertible note receivable | $2.2M | |
| Net cash provided by investing activities | $514.0K | |
| Transaction costs related to the issuance of promissory notes with warrants | -$40.0K | |
| Proceeds from Issuance of promissory notes with warrants | $10.0M | |
| Proceeds from warrants and short-term debt - related parties | $15.0M | |
| Proceeds from issuance of short-term debt - unaffiliated | $3.6M | |
| Repayment of short-term debt - unaffiliated | -$17.4M | |
| Payment of SEPA commitment fee | -$25.0K | |
| Proceeds from the sale of common stock in June 2025 PIPE | $1.0M | |
| Proceeds from the sale of common stock and warrants in July 2025 PIPE | $2.0M | |
| Proceeds from related party note with KTL Warrant | $6.8M | |
| Proceeds from the exercise of stock options | $108.0K | $58.0K |
| Cash proceeds from merchant cash advance | $3.3M | |
| Repayment of merchant cash advance | -$2.6M | |
| Proceeds from the exercise of warrants by Dragasac | $2.5M | |
| Repayment of short-term debt - related party | -$121.0K | -$146.0K |
| Proceeds from issuance of preferred stock with warrants in PIPE Offering | $2.0M | $6.0M |
| Transaction costs from issuing of preferred stock with warrants in PIPE Offering | -$210.0K | |
| Tax withholding on vesting of restricted stock units | -$193.0K | -$434.0K |
| Repayment of related party notes | -$5.9M | |
| Net cash provided by financing activities | $18.6M | $6.7M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $5.4M | $814.0K |
| Cash paid for interest | $2.5M | $144.0K |
| Cash paid for income taxes | $52.0K | |
| Residual fair value of warrants issued with promissory notes | $336.0K | |
| Reclass of redemption value of preferred shares from equity to liability | $300.0K | |
| Conversion of unsecured senior convertible note | $922.0K | |
| Conversion of Yorkville convertible note | $3.5M | |
| Common stock issued for short-term debt conversion | $1.7M | |
| Exchange of IP assets for license obligation | $35.7M | |
| Preferred stock received for product purchase credits | $2.9M | |
| Property and equipment included in accounts payable and accrued expenses | -$87.0K | |
| Reclassification of RWI Bridge warrants from liability classified to equity classified | $8.9M | |
| Reclassification of November 2024 Purchaser and Placement Agent warrants from liability classified to equity classified | $501.0K | |
| Reclassification of KTL Warrants from liability classified to equity classified | $9.2M | |
| Issuance of RWI warrants and extinguishment of promise to issue warrants liability | $1.3M | |
| Deemed dividend relating to inducement of Dragasac warrants | $64.0K | |
| Settlement of contingent stock consideration liability | $27.0K | |
| Paid-in kind preferred stock dividends | $20.0K | |
| Fair value of bifurcated derivative liability associated with Preferred Stock issuance | $157.0K | |
| Modification of C.V. Starr warrants in connection with forbearance | $51.0K | |
| Issuance of RWI warrants in connection with forbearance | $1.2M | |
| Inventory acquired in connection with Rebound asset acquisition | $2.1M | |
| Reclassification of warrants from liability classified to equity classified | $3.0M | |
| Assumption of short-term debt - unaffiliated by related party | $2.3M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Celularity Inc, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
20202025
- Chief executive officerRobert J. Hariri Jul 16, 2021 to now12
- Chief executive officerDean C. Kehler May 20, 2019 to May 20, 201913
- Chief executive officerJay R. Bloom May 20, 2019 to May 20, 201914
- ChairDean C. Kehler May 20, 2019 to May 20, 201913
- ChairJay R. Bloom May 20, 2019 to May 20, 201914
- PresidentAndrew L. Pecora Sep 17, 2021 to Sep 17, 202115
- Chief financial officerJoseph Dossantos Jul 16, 2025 to now16
- Chief financial officerDavid C. Beers Jul 16, 2021 to Jul 16, 202517
- Chief financial officerAndrea J. Kellett May 20, 2019 to May 20, 201918
Board members and other officers (22)
- OfficerKyle Fletcher Feb 22, 2023 to Apr 16, 202419
- OfficerKeary Dunn Apr 28, 2022 to Apr 28, 202220
- OfficerAdrian Kilcoyne Oct 4, 2022 to Feb 21, 202421
- Chief Technical OfficerBradley Glover Jul 16, 2021 to Apr 17, 202322
- Chief Operations & Admin OffcrJohn R. Haines Jul 16, 2021 to now23
- Pres, Functional RegenerationStephen Brigido Jul 16, 2021 to now24
- EVP, Clinical DevelopmentBeloo Mirakhur Sep 15, 2021 to Sep 15, 202125
- Board memberVincent Levien Jul 10, 2025 to now26
- Board memberGeoffrey M.d. Ling Oct 16, 2023 to now27
- Board memberBradley Glover Apr 28, 2022 to Jul 15, 202228
- Board memberDiane L. Parks Jun 3, 2022 to now29
- Board memberEschenbach Andrew C. Von Jul 16, 2021 to Jun 16, 202330
- Board memberJohn Sculley Jul 16, 2021 to Jun 16, 202331
- Board memberKok Thay Lim Jul 16, 2021 to Jun 30, 202332
- Board memberRobert J. Hariri Jul 16, 2021 to now12
- Board memberDean C. Kehler Jul 20, 2021 to Jan 6, 202533
- Board memberJay R. Bloom Jul 20, 2021 to Sep 13, 202134
- Board memberHillel Weinberger May 20, 2019 to May 20, 201935
- Board memberMarc Mazur May 20, 2019 to Jun 16, 202336
- Board memberPaul S. Levy May 20, 2019 to May 20, 201937
- General counselKyle Fletcher Jul 15, 2022 to Nov 18, 202238
- General counselKeary Dunn Jul 16, 2021 to Sep 13, 202139
Former names
- GX Acquisition Corp.Nov 5, 2018 to Jul 19, 20213
Timeline
Filings
370 filings to the SEC since October 2021: 7 annual reports, 14 quarterly reports, 101 major events, 132 insider forms, 19 large holders, 5 private raises, 92 other. The latest 20:
- Sep 29, 20268-K EDGAR
- Sep 29, 202610-Q EDGAR
- Sep 28, 20268-K EDGAR
- Sep 28, 2026SCHEDULE 13D/A EDGAR
- Sep 25, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 25, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 25, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 14, 20268-K EDGAR
- Aug 14, 2026NT 10-Q EDGAR
- Aug 7, 20268-K EDGAR
- Jul 29, 20268-K EDGAR
- Jul 22, 202625-NSE EDGAR
- Jun 30, 20268-K EDGAR
- Jun 25, 20268-K EDGAR
- Jun 23, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 23, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 23, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 23, 2026SCHEDULE 13D/A EDGAR
- Jun 12, 20268-K EDGAR
- Jun 3, 20268-K EDGAR
The 370 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 19 such filings since October 2021, the latest 10:
- Sep 28, 2026SCHEDULE 13D/A
- Jun 23, 2026SCHEDULE 13D/A
- Apr 22, 2026SCHEDULE 13D/A
- Apr 3, 2026SCHEDULE 13D
- Feb 11, 2026SCHEDULE 13G/A
- Aug 27, 2025SCHEDULE 13G
- Jul 28, 2025SCHEDULE 13D/A
- Feb 14, 2025SCHEDULE 13G/A
- Jan 28, 2025SCHEDULE 13D/A
- Dec 19, 2024SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Oct 24, 2025Raised $2 million in a private offering of equity Form D: $6.7 million offered in all Form D
- Jul 30, 2025Raised $2 million in a private offering of equity Form D: 1 investor so far Form D
- Jul 22, 2025Raised $1 million in a private offering of equity Form D: 14 investors so far Form D
- Jul 21, 2025Raised $6.8 million in a private offering of debt Form D: 1 investor so far Form D
- May 20, 2022Raised $30 million in a private offering of equity Form D: 1 investor so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 39. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| C V Starr & Co Inc | 764,069 | $1.6M | 0.8% | No change |
| Vanguard Capital Management LLC | 621,105 | $371.4K | 0.0% | No change |
| Geode Capital Management, LLC | 167,150 | $100.0K | 0.0% | −23,926 |
| Citadel Advisors LLC | 99,054 | $59.2K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 79,874 | $47.8K | 0.0% | No change |
| BlackRock, Inc. | 76,359 | $45.7K | 0.0% | −51,142 |
| State Street Corp | 57,830 | $34.6K | 0.0% | No change |
| Northern Trust Corp | 44,163 | $26.4K | 0.0% | No change |
| Biltmore Family Office, LLC | 35,000 | $20.9K | 0.0% | No change |
| HB Wealth Management, LLC | 31,915 | $19.1K | 0.0% | −8,500 |
| Keynote Financial Services LLC | 29,920 | $17.9K | 0.0% | +600 |
| Jane Street Group, LLC | 28,713 | $17.2K | 0.0% | New |
| CenterStar Asset Management, LLC | 21,000 | $12.9K | 0.0% | +3,150 |
| Royal Bank Of Canada | 18,000 | $11.0K | 0.0% | No change |
| IPG Investment Advisors LLC | 17,169 | $10.3K | 0.0% | No change |
| IFP Advisors, Inc | 12,000 | $7.2K | 0.0% | +4,000 |
| Tower Research Capital LLC (TRC) | 5,111 | $3.1K | 0.0% | +1,847 |
| Group One Trading LLC | 3,595 | $2.1K | 0.0% | +3,500 |
| Wells Fargo & Company/mn | 2,500 | $1.5K | 0.0% | No change |
| Vanguard Global Advisers, LLC | 2,315 | $1.4K | 0.0% | No change |
| SBI Securities Co., Ltd. | 2,284 | $1.4K | 0.0% | +461 |
| Simplex Trading, LLC | 2,188 | $1.3K | 0.0% | +2,133 |
| UBS Group AG | 1,680 | $1.0K | 0.0% | −2,849 |
| Caldwell Sutter Capital, Inc. | 1,000 | $598 | 0.0% | No change |
| Weaver Capital Management LLC | 300 | $399 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCelularity Inc filings on SEC EDGAR
- 2Yahoo FinanceCELU quote
- 3SEC EDGARCelularity Inc filings on SEC EDGAR
- 4SEC EDGARCelularity Inc 10-K for fiscal 2025
- 5SEC EDGARCelularity Inc 10-K for fiscal 2020
- 6SEC EDGARCelularity Inc 10-K for fiscal 2021
- 7SEC EDGARCelularity Inc 10-K for fiscal 2022
- 8SEC EDGARCelularity Inc 10-K for fiscal 2023
- 9SEC EDGARCelularity Inc 10-K for fiscal 2019
- 10SEC EDGARCelularity Inc 10-Q for fiscal 2025
- 11SEC EDGARCelularity Inc 10-Q for fiscal 2026
- 12
- 13
- 14
- 15SEC EDGARAndrew L. Pecora, President
- 16
- 17
- 18
- 19SEC EDGARKyle Fletcher, Officer
- 20SEC EDGARKeary Dunn, Officer
- 21SEC EDGARAdrian Kilcoyne, Officer
- 22
- 23
- 24
- 25
- 26SEC EDGARVincent Levien, Board member
- 27SEC EDGARGeoffrey M.d. Ling, Board member
- 28SEC EDGARBradley Glover, Board member
- 29SEC EDGARDiane L. Parks, Board member
- 30
- 31SEC EDGARJohn Sculley, Board member
- 32SEC EDGARKok Thay Lim, Board member
- 33SEC EDGARDean C. Kehler, Board member
- 34SEC EDGARJay R. Bloom, Board member
- 35SEC EDGARHillel Weinberger, Board member
- 36SEC EDGARMarc Mazur, Board member
- 37SEC EDGARPaul S. Levy, Board member
- 38SEC EDGARKyle Fletcher, General counsel
- 39SEC EDGARKeary Dunn, General counsel